Skip to content

Anti-GP210 Antibody, Serum (Qualitative)

Published: August 9, 2026Updated: August 16, 2026

This test measures whether your body produces antibodies against a specific protein (GP210) found in certain kidney tissues. It may be used to help diagnose or monitor conditions like autoimmune kidney diseases.

Quick summary

["This test helps assess immune responses linked to kidney-related conditions."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
56716-4
Short code
Nuclear pore prot gp210 Ab Ser Ql IB
Synonyms
Nuclear pore prot gp210 Ab Ser Ql IB
Category
chemistry
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Method
ib
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

What This Test Measures

Anti-GP210 antibodies are proteins your immune system makes in response to GP210, a protein found in kidney cells. This test detects their presence in your serum (liquid part of blood). Positive results may indicate an autoimmune reaction targeting kidney tissues, though further evaluation is needed to interpret results clinically.

Why It Might Be Ordered

Your healthcare provider may order this test if you have symptoms like kidney problems (e.g., swelling, fatigue), a history of autoimmune diseases, or if other tests suggest an immune-related kidney condition. It’s often used alongside other diagnostic tools.

How the Test Works

Blood is drawn and tested using an immunoassay method to detect GP210-specific antibodies. The result is qualitative (positive/negative) rather than a numeric value.

What to Expect Before the Test

No special preparation is needed. Wear comfortable clothing, and fast your blood draw as usual unless instructed otherwise.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

Positive results suggest your immune system may be attacking kidney proteins, which could indicate conditions like **Goodpasture syndrome** (autoimmune kidney disease) or other autoimmune disorders. However, false positives can occur, so results are often reviewed with clinical findings. This test is part of a broader evaluation, not a standalone diagnosis.

Short name

Anti-GP210 Ab (Qualitative)

Frequently asked questions

What does a positive result mean?
A positive result indicates your body is producing antibodies against GP210, which may signal an autoimmune process affecting kidney tissues. Your doctor will discuss next steps, such as additional tests or treatments, based on your overall health and symptoms.
Can this test be used to diagnose kidney disease?
No, this test alone cannot diagnose kidney disease. It’s one piece of a puzzle. Doctors use it alongside other tests (e.g., kidney function tests, imaging) to guide diagnosis and treatment.
How often should I get this test?
Frequency depends on your condition. If ordered for monitoring (e.g., autoimmune kidney disease), your doctor may recommend repeat testing based on symptoms or treatment responses. Follow their guidance.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy